Indian Researchers Uncover Novel Gene Mutation Fueling Recurrent Brain Decline in Children

Indian scientists at Indira Gandhi Institute of Child Health in Bangalore have pinpointed a rare mutation in the USP18 gene as the culprit behind repeated neurological episodes in an 11-year-old girl, marking India’s first documented case of Pseudo-TORCH syndrome type 2. This breakthrough, published recently in Clinical Dysmorphology, reveals a previously unknown variant, c.358C>T (p.Pro120Ser), after years of diagnostic uncertainty for the patient who suffered fever-triggered unconsciousness, seizures, developmental delays, microcephaly, and progressive brain calcifications since infancy. The discovery, achieved through advanced exome sequencing in collaboration with Ramjas College, University of Delhi, and Redcliffe Labs, expands global knowledge of a disorder seen in just 11 prior cases worldwide.​

Understanding Pseudo-TORCH Syndrome Type 2

Pseudo-TORCH syndrome type 2 mimics devastating congenital infections like toxoplasmosis or cytomegalovirus—hence the name, standing for “pseudo” Toxoplasma, Other agents, Rubella, Cytomegalovirus, and Herpes simplex—but stems purely from genetic flaws, not pathogens. Children face antenatal or early brain damage, including hemorrhages, calcifications, malformations, microcephaly, seizures, and often liver issues or low platelets, with most succumbing in infancy due to respiratory failure or unrelenting inflammation. Prevalence hovers below 1 in 1,000,000, underscoring its ultra-rarity, yet this Indian case uniquely highlights recurrent febrile encephalopathy—fever-linked brain crises—expanding the syndrome’s profile. ​

The USP18 gene, located on chromosome 22, encodes a protein that acts as a brake on the body’s type I interferon signaling, a key immune pathway that ramps up to fight viruses but can turn destructive if unchecked. Imagine interferon as an overzealous security alarm: USP18 dials it back to prevent false alarms from harming healthy tissues, particularly delicate brain cells; when mutated, this control fails, sparking chronic neuroinflammation akin to an autoimmune attack. In this patient, the novel mutation tweaks the USP18 protein’s structure, crippling its regulatory power and allowing unchecked interferon storms that erode brain function over repeated fevers.​

The Groundbreaking Indian Discovery

The patient’s journey began in infancy with episodic collapses during fevers, misdiagnosed initially as infections, leading to futile antibiotic courses and mounting brain scans revealing calcium buildup. Exome sequencing with mitochondrial analysis finally unmasked the homozygous USP18 variant, confirmed via parental Sanger sequencing showing they carried it asymptomatically—a classic autosomal recessive pattern. This marks not just India’s debut but the 12th global case, with prior reports clustering in diverse ethnicities yet none spotlighting recurrent encephalopathy until now.​

Lead researcher Dr. Vykuntaraju K. Gowda, Pediatric Neurologist at Indira Gandhi Institute, emphasized the shift: “The discovery reinforces clinical intuition backed by genetic testing. For years, we treated symptoms blindly, but this novel USP18 mutation transforms diagnosis and the child’s future”. He added, “It avoids needless therapies, enables precise management, and empowers genetic counseling for families”. Co-researcher Dr. Himani Pandey noted, “This is the first USP18-related case with recurrent febrile encephalopathy,” highlighting its diagnostic novelty.​

Expert Insights and Broader Context

Independent experts applaud the find’s precision. Dr. Yanick Crow, a pioneer in interferonopathies at the University of Edinburgh (not involved), views USP18 defects as emblematic of type I interferonopathies, where genetic tweaks unleash interferon overdrive, mirroring Aicardi-Goutières syndrome. In separate studies, USP18 mutations have shown hypersensitivity to interferon-alpha in patient cells, with elevated inflammatory markers like C-reactive protein and ferritin. Prevalence data pegs pseudo-TORCH type 2 under 1 per million, but underdiagnosis looms in regions like India lacking routine exome access.​

Geneticists stress early testing’s role. Guidelines for recurrent childhood encephalopathies urge whole-exome sequencing when infections are ruled out, especially with calcifications or family history. In India, where consanguinity boosts recessive risks, such tools could unmask more cases, per pediatric neurology consensus.​

Public Health Ramifications and Management Challenges

This revelation urges pediatricians to suspect genetic mimics in “TORCH-like” infants, curbing antibiotic overuse and imaging radiation while fast-tracking counseling. Families gain clarity: prenatal testing or preimplantation diagnosis could prevent transmission in at-risk kin. For patients, supportive care dominates—antiepileptics for seizures, fever control to avert crises, nutritional aids for development, and monitoring calcifications. Emerging interferonopathy therapies intrigue: Janus kinase (JAK) inhibitors like ruxolitinib quelled inflammation in related USP18 cases by blocking interferon paths, hinting at off-label potential.

Yet limitations persist. Studies like this are single-case reports, demanding larger cohorts to affirm the variant’s pathogenicity and phenotype. Variability plagues interferonopathies—some USP18 flaws cause milder survival into childhood, others neonatal death—warranting caution against overgeneralizing. Conflicting data on USP18’s antiviral versus anti-inflammatory roles (e.g., aiding MAVS ubiquitination) complicates therapies. No cure exists; gene therapy remains experimental.​

Future Horizons for Rare Neurological Disorders

This Indian milestone spotlights genomics’ rise in low-resource settings, with labs like Redcliffe Labs scaling affordable exome tests. Globally, it bolsters calls for interferonopathy registries to track variants and trials. For health-conscious families, it reinforces genetic literacy: Unexplained child neurology warrants specialist referral, not panic. As Dr. Gowda notes, timely insights “offer hope where answers were unknown”.​

References